NCT02322814

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: Hoffmann-La Roche

Condition: Breast Cancer

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

Sponsor's decision